S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
Free Trial
OTCMKTS:PNEXF

Pharnext (PNEXF) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)
Free PNEXF Stock Alerts
$400.00
0.00 (0.00%)
(As of 07/13/2023)
Compare
Today's Range
$400.00
▼
$400.00
50-Day Range
$400.00
▼
$4,000,000.00
52-Week Range
$0.0001
▼
$0.0010
Volume
16,660 shs
Average Volume
433 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisHeadlines
PNEXF stock logo

About Pharnext Stock (OTCMKTS:PNEXF)

Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.

PNEXF Stock Price History

PNEXF Stock News Headlines

March 11, 2024 | finanznachrichten.de
PHARNEXT: Pharnext takes full stock of its operating, strategic and financial situation
February 28, 2024 | actusnews.com
Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A
April 19, 2024 | DTI (Ad)
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
February 25, 2024 | benzinga.com
PHARNEXT by Pharnext Stock (OTC:PNEXF), Insider Trading Activity
January 17, 2024 | finanznachrichten.de
PHARNEXT: Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A
January 17, 2024 | actusnews.com
Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A
December 15, 2023 | investing.com
Pharnext set to release pivotal trial data for CMT1A treatment PXT3003
December 2, 2023 | morningstar.com
Pharnext SA ALPHA
April 19, 2024 | Darwin (Ad)
2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
November 20, 2023 | finanznachrichten.de
PHARNEXT: Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States
November 20, 2023 | actusnews.com
Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States
October 16, 2023 | actusnews.com
Pharnext received two offers valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR 250m, and raises EUR 2.5m
September 28, 2023 | actusnews.com
Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A)
July 10, 2023 | finanznachrichten.de
PHARNEXT: Pharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Board
July 10, 2023 | actusnews.com
Pharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Board
June 15, 2023 | actusnews.com
Pharnext appoints Gilbert Wagener, M.D., Ph.D. as Chief Medical Officer
June 8, 2023 | actusnews.com
Pharnext supports and participates in the First European Charcot-Marie-Tooth disease Specialists Conference
May 22, 2023 | finanznachrichten.de
PHARNEXT: Edison Investment Research publishes updates research report on Pharnext
May 12, 2023 | finanznachrichten.de
PHARNEXT: Pharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)
May 12, 2023 | actusnews.com
Pharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)
May 5, 2023 | finance.yahoo.com
Global Dental Partnering 2010-2023: Deal Trends, Players and Financials
April 18, 2023 | actusnews.com
Pharnext supports the online 2023 Conference of CMTUK, the UK's Charity dedicated to supporting people living with Charcot-Marie-Tooth disease
March 20, 2023 | finanznachrichten.de
PHARNEXT: Pharnext supports and participates in two congresses on Neuromuscular Disorders in Europe
March 20, 2023 | actusnews.com
Pharnext supports and participates in two congresses on Neuromuscular Disorders in Europe
March 14, 2023 | actusnews.com
Pharnext supports and participates in two congresses dedicated to Charcot-Marie-Tooth diseases in Marseille, France
March 6, 2023 | finanznachrichten.de
PHARNEXT: Pharnext supports and participates in the 27th edition of the Francophone Peripheral Nerve Society conference (SFNP) in Paris
February 15, 2023 | finance.yahoo.com
Pharnext SA (ALPHA.PA)
See More Headlines
Receive PNEXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharnext and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:PNEXF
CUSIP
N/A
CIK
N/A
Web
www.pharnext.com
Phone
(314) 109-2230
Fax
N/A
Employees
23
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Daniel E. Cohen (Age 70)
    Director
    Comp: $343.16k
  • Mr. Hugo Brugiere M.Sc.
    CEO & Chairman
  • Mr. Ilya Chumakov Ph.D.
    D-Sc, Co-Founder, Chairman of Scientific Advisory Board and Director
  • Mr. Xavier Paoli M.Sc.
    Chief Operating Officer
  • Mr. Vincent Serra Ph.D. (Age 53)
    COO & Chief Scientific Officer
  • Mr. Abhijit Pangu
    Head of Regulatory Affairs
  • Mr. Raj Thota M.Sc.
    Chief Manufacturing Officer & Head of CMC
  • Mr. Scott Johnson B.Sc.
    VP & Head of Quality
  • Mr. Gilbert Wagener M.D.
    Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

PNEXF Stock Analysis - Frequently Asked Questions

How have PNEXF shares performed in 2024?

Pharnext's stock was trading at $4,000,000.00 at the beginning of the year. Since then, PNEXF shares have decreased by 100.0% and is now trading at $400.00.
View the best growth stocks for 2024 here.

When did Pharnext's stock split?

Pharnext shares reverse split on the morning of Thursday, February 15th 2024. The 1-10000 reverse split was announced on Thursday, February 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Pharnext?

Shares of PNEXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PNEXF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith